tirzepatide injection vs semaglutide Wondering about the difference between

Ivanov, D., Martinez, A., & Singh, R

1 3 2 1 2 GIPGLP-12 [1] 2[1] 20234 2.5mg415mg[1] GLP-1[2] GLP-1 [2] 1 0.25mg40.5mg1.0mg[2] GIP+GLP-1GLP-1 GLP-1 GLP-1GIP [1][2] GIP GLP-1 SURPASS-2SURMOUNT-5 21,879SURPASS-2 4015mg11.2kg 1mg5.7kg [3] SURMOUNT-57220.2%13.7%[4] 15mg9.5kg[5] 23 2.5mg5mg 0.25mg0.51.0mg 246[3][4] [1][2] GLP-1 24 1620%1822%[6] GIPGLP-1 [1] GLP-1 [1][2] 1 2 2.5mg120,00030,0005mg30,00055,000 2.0mg1420,00025,000 10mg150,000 2 [1][2] 35mg14,6001.0mg6,500 2.5mg11,9245mg13,848[1] 1 1 2.5mg45mg7.5mg10mg12.5mg15mg6 [1] 0.25mg40.5mg41.0mg3[2] [1] [2] GLP-1 2 1[7] 15mg9.5kg1.0mg4.4kg14mg2.6kg[5] 110,00030,000 30[7] GIPGLP-120% BMI [4] 2.5mg15mg6 GLP-1 2 [1][2] Q1

This multi-target design represents a significant advance beyond both the single-agonist GLP-1 receptor agonists (such as semaglutide) and the dual GIP/GLP-1 agonists (such as tirzepatide)

, ,